romiplostim + lenalidomide

**Romiplostim + lenalidomide** is an experimental drug combination consisting of two distinct agents: - **Romiplostim** is a thrombopoietin receptor agonist (TPO-RA), specifically a fusion protein (peptibody) that activates the thrombopoietin receptor (c-Mpl) on megakaryocyte precursors, stimulating their proliferation and differentiation to increase platelet production and thus reduce thrombocytopenia[2][4]. - **Lenalidomide** is an immunomodulatory small molecule agent and a thalidomide analog that is primarily used in the treatment of myelodysplastic syndromes (MDS) and multiple myeloma. This combination has been investigated in clinical trials, primarily in patients with lower-risk myelodysplastic syndromes (MDS), with the goal of reducing thrombocytopenia (a side effect of lenalidomide) and associated dose modifications by providing romiplostim concurrently[1][3]. The primary rationale is that romiplostim can help mitigate lenalidomide-induced thrombocytopenia by increasing platelet production.